$4.30
0.4010.26%
Last update: Nov 11, 6:38 PM
Prime Medicine Inc
PRMENASDAQ
Prime Medicine rose 21.1% from $3.55 to $4.30, ahead of the S&P 500's +11.2%. Its worst day was Jun 5 (−11.8%), and its low came May 19 at $2.70.
Nov 12, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Prime Medicine shares rose 16.6%, while the S&P 500 rose 0.5%.
+16.6% · S&P 500 +0.5%
EPS of $-0.24 beat the $-0.25 estimate on $838,000.00 revenue (est. $2.2M).
−9.2% · S&P 500 −0.9%
Story events cover the past 12 months · Times ET
EPS of $-0.28 missed the $-0.25 estimate on $856,000.00 revenue (est. $1.0M).
−8.7% · S&P 500 −0.3%
Prime Medicine closed at its lowest level of the year, 23.9% below where the year started.
−3.9% · S&P 500 −0.7%
-- Arbitration tribunal declared that PM647 is within Prime Medicine’s "Field", confirming Prime Medicine’s right to develop and commercialize PM647 in AATD ---- Prime Medicine owes no monetary damages to Beam
+15.8% · S&P 500 −0.3%
EPS of $-0.24 beat the $-0.25 estimate on $1.2M revenue (est. $1.8M).
−4.2% · S&P 500 −0.2%
Prime Medicine shares rose 16.1%, while the S&P 500 rose 0.2%.
+16.1% · S&P 500 +0.2%
Prime Medicine shares rose 15.3%, while the S&P 500 rose 0.3%.
+15.3% · S&P 500 +0.3%
Prime Medicine closed at its highest level of the year, 51.0% above where the year started.
+23.2%, the year's best day · S&P 500 +0.3%
Where it ended: a close of $4.30 on Nov 11, 2026. Up next: Q3 2026 earnings on Nov 24, 2026 (EPS est. $-0.24, revenue est. $2.0M).
Nothing in the past 12 months.
All PRME dividend historyAs of the Nov 11, 2026 close
Replay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for PRME and SPY from Benzinga historical bars. Not investment advice.
